A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
DRUG: Tegafur and Temozolomide|DRUG: Tegafur and Temozolomide combined with Thalidomide
Objective Response Rate(ORR), From randomization，each 6 weeks or 12 weeks(a year later) up to intolerance the toxicity or PD (up to 24 months)
Disease Control Rate(DCR), From randomization，each 6 weeks or 12 weeks(a year later) up to intolerance the toxicity or PD (up to 24 months|Time to Tumor Response (TTR), From randomization，each 6 weeks or 12 weeks(a year later)up to PD or death(up to 24 months)|Duration of Response(DOR), From randomization，each 6 weeks or 12 weeks(a year later) up to PD or death(up to 24 months)|Progression free survival(PFS), From randomization，each 6 weeks or 12 weeks(a year later)(a year later) up to PD or death (up to 24 months)
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor